Key facts
- FutureMeds’s last known valuation is $1.2M (May 2020).
- It has raised $760K; the latest was PE Growth/Expansion in Jul 2025.
- Notable investors include Phoenix Equity Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for FutureMeds
- ·The full record, as it builds
Funding rounds
No funding rounds for FutureMeds are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FutureMeds
Provider of clinical trial and therapy services intended to optimize research processes. The company supports patient recruitment, trial management, and monitoring, incorporating both traditional and decentralized methods, enabling pharmaceutical and biotechnology companies to conduct effective trials, improve patient engagement, and achieve reliable results across diverse therapeutic areas.
- Sector
- Healthcare
- HQ
- United Kingdom
- Founded
- 2019
- Employees
- 397
- Website
- futuremeds.com/
- Ownership
- Privately Held (backing)
FutureMeds doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FutureMeds shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FutureMeds in its N-PORT filings yet. We sweep new filings monthly.